Abiraterone Before Chemotherapy a Successful Strategy in Prostate Cancer

August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective - Prostate Cancer
Wayne Kuznar

Chicago, IL—Abiraterone acetate (Zytiga) delays disease progression when used with prednisone before chemotherapy in men with metastatic castration-resistant prostate cancer, said Charles J. Ryan, MD, Associate Professor of Clinical Med­icine, Helen Diller Family Compre­hensive Cancer Center at the University of California, San Fran­cisco, who reported a planned interim analysis of a phase 3 study at ASCO 2012.

The finding represents a potential new use of abiraterone in prostate cancer; the drug is now approved only for men with metastatic castration-resistant prostate cancer in whom do­cetaxel (Taxo­tere) chemo­­therapy has failed.

“These data merit consideration as providing a new standard approach in this highly prevalent population faced with an unmet medical need,” said Dr Ryan.

The trial included 1088 men with metastatic castration-resistant prostate cancer that was no longer responsive to hormonal therapy. The men were randomized to abiraterone plus prednisone or to placebo plus prednisone.

The trial was terminated early, with 43% of total events reported, given the favorable response on overall survival (OS) and progression-free survival (PFS) observed with abiraterone. At this point, the Independent Data Monitoring Committee recommended un­blinding the study and offering the placebo recipients active treatment with abiraterone.

The median survival in this study was 14.8 months, with an improvement of 3.9 months over the prednisone control arm, “thus reflecting the advanced clinical stage of the population tested,” said Dr Ryan.

“A reality is that much of the life of a patient with metastatic castration-resistant prostate cancer is lived before chemotherapy, and, in fact, a large proportion of patients never receive it,” Dr Ryan stated in explaining the rationale for studying abiraterone in chemotherapy-naïve patients.

There was a 57% improvement in radiographic PFS, a coprimary end point, in men randomized to abir­aterone. The median time to progression was 8.3 months in the control group, but the median time to PFS had not yet been reached in the abir­aterone group at the time the trial was sus­pended. “This represents an approx­imate doubling of the radio­graphic progression-free survival,” he said.

The median survival in the prednisone control arm was 27.2 months, whereas the median survival had not yet been reached in the abiraterone arm, which conforms to a 25% improvement in survival, “a strong trend in favor of abiraterone,” Dr Ryan pointed out. This trend did not reach statistical significance because of the early termination of the trial.

Some 60.3% of the prednisone control group required additional therapies for prostate cancer, including do­cetaxel (the most common subsequent treatment) compared with only 44.3% of the abir­aterone arm.

Abiraterone significantly de­layed the time (by 31%) before patients needed opiates to control pain and the time (by 42%) to initiate chemotherapy.

Susan Halabi, PhD, Associate Pro­fessor of Biostatistics and Bio­infor­matics at Duke University Medical Center, Durham, NC, said that although the study represents the first to show activity of abiraterone in chemotherapy-naïve patients, she questioned early termination of the trial, before the difference in OS observed with abiraterone could achieve statistical significance.

Never­theless, the survival benefit with abiraterone is most likely real, she said.—WK
 

Related Items
The Pediatric MATCH Study: Actionable Targets Found in 25% of Young Patients with Cancer
Wayne Kuznar
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in Pediatric Cancer
Autologous Mesothelin-Targeted T-Cells Induce Responses in Pleural Solid Tumors
Wayne Kuznar
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in Emerging Therapies
Selective, Small-Molecule DRD2 Antagonist Induces Tumor Regression in Recurrent High-Grade Glioma
Wayne Kuznar
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in Emerging Therapies
Expanding Treatment Options for Patients with Advanced Cholangiocarcinoma
Wayne Kuznar
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in Cholangiocarcinoma
Larotrectinib Has Wide-Ranging Efficacy in Advanced Solid Tumors with NTRK Gene Fusion
Wayne Kuznar
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in Biomarkers
Last modified: August 30, 2012
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME